http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/list Mynewsdesk nyhetsfeed direkt från källan http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/list http://www.mynewsdesk.com/images/redesign/graphics/logos/logo-small.png 128 23 sv 15 Thu, 17 Mar 2011 18:06:50 +0100 http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-to-offer-donation-to-tohoku-pacific-earthquake-599943?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-to-offer-donation-to-tohoku-pacific-earthquake-599943?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Tue, 31 Aug 2010 16:46:00 +0200 Från den 17 augusti tog Clas Lindbergson över som Managing Director Nordic för Eisai AB..Det har gått fyra år sedan det japanska läkemedelsföretaget etablerade sig i Norden. Idag, 25 anställda och sju produkter senare, är det dags att ta steget vidare in i nya sjukdomsområden under en ny ledning. http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/ny-ledning-foer-eisai-inom-norden-461634?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/ny-ledning-foer-eisai-inom-norden-461634?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Tue, 24 Aug 2010 11:58:31 +0200 Hatfield, UK, 24 August 2010 – Eisai today announced the results of a Phase III study for the investigational compound perampanel (E2007), a first-in-class, highly selective non-competitive AMPA-type glutamate receptor antagonist, discovered by Eisai and under development for adjunctive treatment of partial seizures in patients with epilepsy. http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-announces-positive-phase-iii-trial-results-for-perampanel-in-partial-epilepsy-456879?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-announces-positive-phase-iii-trial-results-for-perampanel-in-partial-epilepsy-456879?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Wed, 09 Jun 2010 14:57:10 +0200 Global EMBRACE-studie jämförde eribulin med behandling enligt läkarens val http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/studieresultaten-foer-fas-iii-visade-att-eisais-eribulinmesylat-ger-hoegre-total-oeverlevnad-hos-patienter-med-lokalt-recidiverande-eller-422481?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/studieresultaten-foer-fas-iii-visade-att-eisais-eribulinmesylat-ger-hoegre-total-oeverlevnad-hos-patienter-med-lokalt-recidiverande-eller-422481?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Mon, 07 Jun 2010 17:11:20 +0200 Global EMBRACE Study Compared Eribulin to Treatment of Physician’s Choice http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/phase-iii-study-results-showed-eisais-eribulin-mesylate-significantly-improved-overall-survival-in-patients-with-locally-recurrent-or-metastatic-421191?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/phase-iii-study-results-showed-eisais-eribulin-mesylate-significantly-improved-overall-survival-in-patients-with-locally-recurrent-or-metastatic-421191?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Thu, 01 Apr 2010 12:00:00 +0200 LONDON, UK, 31 March 2010 — Eisai Europe Ltd. today announced that it has submitted a marketing authorization application to the European Medicines Agency (EMA) for approval of eribulin mesylate, also known as ‘E7389’, for the treatment of locally advanced or metastatic breast cancer in Europe. http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-submits-marketing-authorization-application-for-approval-of-eribulin-mesylate-in-europe-based-on-significant-overall-survival-in-late-stage-391358?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-submits-marketing-authorization-application-for-approval-of-eribulin-mesylate-in-europe-based-on-significant-overall-survival-in-late-stage-391358?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Mon, 21 Dec 2009 07:30:00 +0100 Eisai Obtains Worldwide Rights to Develop, Market and Manufacture AKR-501, Therapeutic Agent for Thrombocytopenia http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-initiates-procedures-to-acquire-akarx-inc-in-the-united-states-355994?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-initiates-procedures-to-acquire-akarx-inc-in-the-united-states-355994?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Mon, 21 Dec 2009 07:00:00 +0100 Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Hauro Naito) today announced the completion of construction of the Eisai Knowledge Centre, India, the Company’s new manufacturing and process research base in India. http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-opens-new-manufacturing-and-process-research-base-in-india-355992?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-opens-new-manufacturing-and-process-research-base-in-india-355992?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Tue, 10 Nov 2009 07:00:00 +0100 http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/global-phase-iii-study-results-show-eribulin-meets-primary-endpoint-of-overall-survival-339517?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/global-phase-iii-study-results-show-eribulin-meets-primary-endpoint-of-overall-survival-339517?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Wed, 07 Oct 2009 13:31:37 +0200 Den store andel af epilepsipatienter, der stadig får anfald trods medicinsk behandling, får nu en ny mulighed for at nedbringe deres anfaldsfrekvens. En ny tillægsbehandling Zebinix (eslicarbazepinacetat) til voksne patienter med partielle anfald giver således mulighed for nedsat anfaldsfrekvens og forhøjet livskvalitet med én pille om dagen. http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/banebrydende-antiepileptikum-lanceres-i-danmark-327043?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/banebrydende-antiepileptikum-lanceres-i-danmark-327043?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Thu, 24 Sep 2009 13:56:15 +0200 A subsidiary of Eisai Corporation of North America, Morphotek®, Inc., today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumb in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA). http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/farletuzumab-data-presented-on-phase-ii-clinical-trial-in-first-relapsed-ovarian-cancer-subjects-322447?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/farletuzumab-data-presented-on-phase-ii-clinical-trial-in-first-relapsed-ovarian-cancer-subjects-322447?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Fri, 15 May 2009 07:00:00 +0200 Leva med epilepsi är resultatet av ett gränsöverskridande samarbete mellan professionen, patientföreningar, folkbildningsorganisationer, Eisai och kända samt okända personer med epilepsi. Resultatet är en kombination av medicinsk vetenskap och det mänskliga mötet och syftet är folkbildning. Intresset för boken har varit mycket stort och följs nu upp i form av en ”Road Show” ... http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/bok-om-epilepsi-blir-till-road-show-294640?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/bok-om-epilepsi-blir-till-road-show-294640?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Thu, 30 Apr 2009 09:00:00 +0200 http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/novel-once-daily-anti-epileptic-zebinix-approved-in-the-european-union-290952?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/novel-once-daily-anti-epileptic-zebinix-approved-in-the-european-union-290952?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Thu, 12 Mar 2009 14:55:00 +0100 Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced that it has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma. The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma. http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/morphotek-r-inc-announces-initiation-of-morab-009-phase-ii-study-in-first-line-treatment-of-mesothelioma-279152?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/morphotek-r-inc-announces-initiation-of-morab-009-phase-ii-study-in-first-line-treatment-of-mesothelioma-279152?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Tue, 24 Feb 2009 11:37:00 +0100 Eisai Europe Ltd (London; Chairman & CEO Yutaka Tsuchiya), the European subsidiary of Eisai Co., Ltd. (Tokyo, President & CEO: Haruo Naito), and Bial-Portela & CA, S.A., (S. Mamede do Coronado, Portugal, CEO Dr Luis Portela) today announced the signing of a licence and co-promotion agreement in which Eisai receives a sole license to market, http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-and-bial-announce-partnership-agreement-for-the-european-commercialisation-of-the-novel-once-daily-anti-epileptic-zebinix-291420?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-and-bial-announce-partnership-agreement-for-the-european-commercialisation-of-the-novel-once-daily-anti-epileptic-zebinix-291420?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Tue, 24 Feb 2009 09:42:00 +0100 Eisai och Bial tillkännager samarbetsavtal gällande marknadsföring i Europa av Zebinix, ett nytt medel mot epilepsi. Detta är en unik möjlighet... och ger Eisai en ledande ställning inom terapiområde epilepsi, säger Christer Ahlberg, VD för Eisai i Norden. (Läs mer i bifogad pressrelease.) http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-paa-vaeg-att-bli-en-av-de-ledande-inom-epilepsiomraadet-274488?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/eisai-paa-vaeg-att-bli-en-av-de-ledande-inom-epilepsiomraadet-274488?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Thu, 22 Jan 2009 10:00:00 +0100 Nästan varannan svensk har en person med epilepsi i sin närhet. Ändå vet 8 av 10 inte hur de ska agera när någon får ett epileptiskt anfall. http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/celebriteter-tar-upp-kampen-mot-okunskapen-kring-epilepsi-274085?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/celebriteter-tar-upp-kampen-mot-okunskapen-kring-epilepsi-274085?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB Tue, 27 Mar 2007 10:25:00 +0200 Nu introduceras ett nytt läkemedel i Sverige, Prialt® (ziconotide). Prialt är godkänt för behandling av svår kronisk smärta hos patienter som behöver intratekal smärtbehandling. Prialt erbjuder nytt hopp för patienter som trots behandling med starka smärtläkemedel eller andra smärtlindrande metoder fortfarande lider av svår smärta. http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/nytt-smaertlaekemedel-prialt-ziconotide-fraan-tropisk-havssnigel-till-modernt-smaertlaekemedel-138963?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease http://www.mynewsdesk.com/se/pressroom/eisai/pressrelease/view/nytt-smaertlaekemedel-prialt-ziconotide-fraan-tropisk-havssnigel-till-modernt-smaertlaekemedel-138963?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease Eisai AB